Loading...
XHKG
1858
Market cap648mUSD
Jul 10, Last price  
8.73HKD
1D
2.34%
1Q
-33.86%
Jan 2017
246.43%
IPO
-42.34%
Name

Beijing Chunlizhengda Medical Instruments Co Ltd

Chart & Performance

D1W1MN
XHKG:1858 chart
P/E
16.51
P/S
4.30
EPS
0.46
Div Yield, %
3.33%
Shrs. gr., 5y
2.09%
Rev. gr., 5y
2.21%
Revenues
1.05b
+29.77%
98,094,696110,545,519134,534,445177,368,809207,926,096300,317,298497,927,159855,326,545937,686,1851,108,139,5201,201,604,2541,208,523,845805,857,0211,045,766,405
Net income
273m
+118.05%
31,939,63632,665,36137,031,19737,865,61763,440,59068,283,986105,646,070236,761,397283,373,280322,360,736307,719,145277,824,014124,988,009272,542,347
CFO
410m
P
28,827,96928,202,52724,274,585064,945,27289,833,114108,506,202231,540,264260,682,359164,785,78641,007,526511,713,888-1,899,550409,567,403
Dividend
Nov 24, 20250.2304 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Beijing Chunlizhengda Medical Instruments Co., Ltd. functions as a prominent entity within the orthopedic medical device industry, dedicated to the development, manufacturing, and distribution of surgical implants, instruments, and associated medical supplies throughout the People's Republic of China. Its core product range features implantable orthopedic solutions, specifically comprising joint prostheses and spinal treatment products. The company predominantly distributes its merchandise via an expansive network of distributors, through original design manufacturing (ODM) and original equipment manufacturing (OEM) partnerships under the 'Chunli' label, and by direct sales to healthcare institutions. Beyond its domestic operations, the firm also engages in exporting its products to various countries globally. Established in 1998, its corporate headquarters are situated in Beijing, China.
IPO date
Dec 30, 2021
Employees
1,379
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT